Protection of Saxagliptin for liver inflammatory injury in rat model of diabetes complicating with nonalcoholic fatty liver disease and its mechanism / 中华内分泌代谢杂志

ABSTRACT

[Summary] Thirty-two SD rats were randomly divided into noraml control group(NC, n = 10) and high fat diet group(HF, n=22). 10 weeks later, the HF group rats were injected STZ(30 mg/ kg) to set up the model of diabetes complicating with nonalcoholic fatty liver disease (NAFLD). Then, HF group were randomly divided into model control group(MC, n = 8) and Saxagliptin intervene group( M + S, n = 8). The M + S group were made an intervention with Saxagliptin(10 mg·kg-1 ·d-1 ) for 8 weeks. At the end of 18 weeks, the fasting blood glucose, serum insulin, liver function, liver weight, tumor necrosis factor alpha, and interleukin 6 were measured. HOMA-IR was calculated. Western bolt was used to determine the expression of NF-κB in hepatic tissue. The level of the indexes above increased in the MC group than in the NC group. But the indexes above mentioned in M + S group were ameliorated. The expression of NF-κB was significantly up regulated in MC group as compared with the NC group, and significantly reduced in the M+S group than in the MC group. The results of correlation analysis revealed that TNF-αand IL-6 were positive correlated with HOMR-IR, respectively. Saxagliptin can effectively reduce the blood glucose level and alleviate insulin resistance, then further relieve the inflammation of liver injury, and finally to alleviate the condition of T2DM with NAFLD. It may play a protective role in the damaged hepatic cells.